A Phase 3 interventional study of Cefazolin IV and Linezolid IV in Bacteremia and Gram-Positive Bacterial Infections, sponsored by Pfizer. Terminated at 17 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-08-07.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will treat hemodialysis patients who have a central catheter that is thought to be infected with a specific bacteria (Gram positive bacteria).
Pfizer suspended enrollment on 21 August 2006 as a precautionary measure in light of the mortality imbalance seen in a similar study, and terminated the study on April 6, 2007 due to factors affecting the timeline to completion, such as slow enrollment and inclusion of sufficient evaluable subjects.
298 studies on the registry are indexed under Bacteremia; 51 are open to participants now.
This study's enrollment of 61 is below the median of 156 across 156 interventional studies indexed under Bacteremia.
Browse Bacteremia studies →Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Number of Participants With Microbiological Response at Test-of-Cure (TOC) Visit
Microbiological response assessed at participant level. Eradication = baseline isolate not present in repeat culture from the original infection site; Presumed Eradication = clinical response of cure based on Sponsor's (Sp) assessment, culture data not available for participants; Persistence = baseline isolate present in repeat culture from the original infection site; Presumed Persistence = culture data not available for participants with a clinical response of failure based on Sp assessment.
Time frame: Short term follow-up (STFU) visit for TOC (2 to 3 weeks after the last dose of study medication)
Number of Participants With Clinical Outcome Based on Sponsor's (Sp) and Investigator's (Ir) Assessment
Ir assessment Cure: clinical signs/symptoms of infection (SSx) resolved and no reoccurrence; Improvement: Moderate resolution of SSx, no additional antibiotic needed; Failure: persistence/progression of baseline SSx, new clinical findings; Indeterminate: circumstances precluding above classification. Sp assessment Failure: concomitant antibiotic after day 3 up to/including Ir assessment day at TOC/upper limit of TOC window (if no Ir assessment at TOC), no Ir assessment at end of treatment (EOT) and TOC; Indeterminate: Sp assessment cured/ improved at EOT, no Ir assessment at TOC/indeterminate.
Time frame: EOT (within 72 hours after last dose of study medication), STFU visit for TOC (2 to 3 weeks after the last dose of study medication), Long term follow-up (LTFU) visit (6 to 8 weeks after the last dose of study medication)
Number of Participants With Complications During Therapy
Late metastatic sequelae associated with Gram positive bacterial infections: abdominal abscess, brain abscess, meningitis, septic arthritis, osteomyelitis, endocarditis, empyema, spinal epidural abscess, intracerebral epidural abscess, septic phlebitis and septic thrombophlebitis.
Time frame: LTFU visit (6 to 8 weeks after the last dose of study medication)
Percentage of Pathogens Eradicated
Eradication included Documented or Presumed Eradication of the given pathogen. Percentage of pathogen eradicated was calculated as number of pathogens eradicated divided by number of pathogens eradicated or persisted multiplied by 100.
Time frame: STFU visit for TOC (2 to 3 weeks after the last dose of study medication), LTFU visit (6 to 8 weeks after the last dose of study medication)
Percentage of Participants With Eradication of Staphylococcus Aureus Nasal Colonization
Eradication was defined as the absence of the original baseline nasal Staphylococcus aureus isolated in nasal swab culture.
Time frame: STFU visit for TOC (2 to 3 weeks after the last dose of study medication), LTFU visit (6 to 8 weeks after the last dose of study medication)
| Milestone | Linezolid | Vancomycin/Cefazolin |
|---|---|---|
| Started | 30 | 31 |
| Completed | 9 | 14 |
| Not completed | 21 | 17 |
| Withdrew: Lack of efficacy | 1 | 2 |
| Withdrew: Death | 3 | 0 |
| Withdrew: Adverse event | 3 | 1 |
| Withdrew: Other | 14 | 14 |
Microbiological response assessed at participant level. Eradication = baseline isolate not present in repeat culture from the original infection site; Presumed Eradication = clinical response of cure based on Sponsor's (Sp) assessment, culture data not available for participants; Persistence = baseline isolate present in repeat culture from the original infection site; Presumed Persistence = culture data not available for participants with a clinical response of failure based on Sp assessment.
No measurements were reported for this outcome.
Ir assessment Cure: clinical signs/symptoms of infection (SSx) resolved and no reoccurrence; Improvement: Moderate resolution of SSx, no additional antibiotic needed; Failure: persistence/progression of baseline SSx, new clinical findings; Indeterminate: circumstances precluding above classification. Sp assessment Failure: concomitant antibiotic after day 3 up to/including Ir assessment day at TOC/upper limit of TOC window (if no Ir assessment at TOC), no Ir assessment at end of treatment (EOT) and TOC; Indeterminate: Sp assessment cured/ improved at EOT, no Ir assessment at TOC/indeterminate.
No measurements were reported for this outcome.
Late metastatic sequelae associated with Gram positive bacterial infections: abdominal abscess, brain abscess, meningitis, septic arthritis, osteomyelitis, endocarditis, empyema, spinal epidural abscess, intracerebral epidural abscess, septic phlebitis and septic thrombophlebitis.
No measurements were reported for this outcome.
Eradication included Documented or Presumed Eradication of the given pathogen. Percentage of pathogen eradicated was calculated as number of pathogens eradicated divided by number of pathogens eradicated or persisted multiplied by 100.
No measurements were reported for this outcome.
Eradication was defined as the absence of the original baseline nasal Staphylococcus aureus isolated in nasal swab culture.
No measurements were reported for this outcome.
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Linezolid | — | 7/30 (23.3%) | 12/30 (40%) |
| Vancomycin/Cefazolin | — | 3/31 (9.7%) | 9/31 (29%) |
| Event | Linezolid | Vancomycin/Cefazolin |
|---|---|---|
| Cardiopulmonary failureCardiac disorders | 1/30 | 0/31 |
| Myocardial infarctionCardiac disorders | 1/30 | 0/31 |
| Duodenal ulcerGastrointestinal disorders | 1/30 | 0/31 |
| VomitingGastrointestinal disorders | 1/30 | 0/31 |
| ChillsGeneral disorders | 1/30 | 0/31 |
| PyrexiaGeneral disorders | 1/30 | 1/31 |
| BronchopneumoniaInfections and infestations | 1/30 | 0/31 |
| EndocarditisInfections and infestations | 1/30 | 0/31 |
| Fluid overloadMetabolism and nutrition disorders | 1/30 | 0/31 |
| Hypertensive crisisVascular disorders | 1/30 | 0/31 |
| Event | Linezolid | Vancomycin/Cefazolin |
|---|---|---|
| VomitingGastrointestinal disorders | 6/30 | 1/31 |
| PyrexiaGeneral disorders | 2/30 | 3/31 |
| NauseaGastrointestinal disorders | 2/30 | 1/31 |
| Supraventricular tachycardiaCardiac disorders | 1/30 | 0/31 |
| Abdominal pain upperGastrointestinal disorders | 1/30 | 0/31 |
| DyspepsiaGastrointestinal disorders | 1/30 | 1/31 |
| Gastric ulcerGastrointestinal disorders | 1/30 | 0/31 |
| GastritisGastrointestinal disorders | 1/30 | 0/31 |
| OesophagitisGastrointestinal disorders | 1/30 | 0/31 |
| CandidiasisInfections and infestations | 1/30 | 0/31 |
| Age Continuous(years) | Linezolid | Vancomycin/Cefazolin | Total |
|---|---|---|---|
| Mean | 54.4 ± 17.7 | 49.7 ± 15.4 | 52.0 ± 16.6 |
| Sex: Female, Male(Participants) | Linezolid | Vancomycin/Cefazolin | Total |
|---|---|---|---|
| Female | 13 | 13 | 26 |
| Male | 17 | 18 | 35 |
The record gives a start of Sep 2005 and a completion of Sep 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cefazolin · Linezolid · Vancomycin